BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 15454952)

  • 1. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
    Bessis N; GarciaCozar FJ; Boissier MC
    Gene Ther; 2004 Oct; 11 Suppl 1():S10-7. PubMed ID: 15454952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of the inflammatory response to adenovirus vectors.
    Liu Q; Muruve DA
    Gene Ther; 2003 Jun; 10(11):935-40. PubMed ID: 12756413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate immune response induced by gene delivery vectors.
    Sakurai H; Kawabata K; Sakurai F; Nakagawa S; Mizuguchi H
    Int J Pharm; 2008 Apr; 354(1-2):9-15. PubMed ID: 17640834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
    Zaiss AK; Muruve DA
    Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.
    Jooss K; Chirmule N
    Gene Ther; 2003 Jun; 10(11):955-63. PubMed ID: 12756416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity.
    Schulick AH; Vassalli G; Dunn PF; Dong G; Rade JJ; Zamarron C; Dichek DA
    J Clin Invest; 1997 Jan; 99(2):209-19. PubMed ID: 9005989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.
    Schagen FH; Ossevoort M; Toes RE; Hoeben RC
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):51-70. PubMed ID: 15094159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity to islet grafts transduced with adenovirus vectors does not inhibit long-term islet function.
    Cheng J; Sun J; Sung RS
    Transpl Immunol; 2009 May; 21(1):33-42. PubMed ID: 19224710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.
    Benihoud K; Esselin S; Descamps D; Jullienne B; Salone B; Bobé P; Bonardelle D; Connault E; Opolon P; Saggio I; Perricaudet M
    Gene Ther; 2007 Mar; 14(6):533-44. PubMed ID: 17109009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors.
    Zepeda M; Wilson JM
    Gene Ther; 1996 Nov; 3(11):973-9. PubMed ID: 8940637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function.
    Chen D; Murphy B; Sung R; Bromberg JS
    Gene Ther; 2003 Jun; 10(11):991-8. PubMed ID: 12756420
    [No Abstract]   [Full Text] [Related]  

  • 13. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
    Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antivector and antitransgene host responses in gene therapy.
    Hackett NR; Kaminsky SM; Sondhi D; Crystal RG
    Curr Opin Mol Ther; 2000 Aug; 2(4):376-82. PubMed ID: 11249767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circumventing the immune response to adenovirus-mediated gene therapy.
    Kass-Eisler A; Leinwand L; Gall J; Bloom B; Falck-Pedersen E
    Gene Ther; 1996 Feb; 3(2):154-62. PubMed ID: 8867863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys.
    Haegel-Kronenberger H; Haanstra K; Ziller-Remy C; Ortiz Buijsse AP; Vermeiren J; Stoeckel F; Van Gool SW; Ceuppens JL; Mehtali M; De Boer M; Jonker M; Boon L
    Gene Ther; 2004 Feb; 11(3):241-52. PubMed ID: 14737083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
    Kuzmin AI; Galenko O; Eisensmith RC
    Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
    Varnavski AN; Calcedo R; Bove M; Gao G; Wilson JM
    Gene Ther; 2005 Mar; 12(5):427-36. PubMed ID: 15647774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.
    Muruve DA; Cotter MJ; Zaiss AK; White LR; Liu Q; Chan T; Clark SA; Ross PJ; Meulenbroek RA; Maelandsmo GM; Parks RJ
    J Virol; 2004 Jun; 78(11):5966-72. PubMed ID: 15140994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent.
    Appledorn DM; Kiang A; McBride A; Jiang H; Seregin S; Scott JM; Stringer R; Kousa Y; Hoban M; Frank MM; Amalfitano A
    Gene Ther; 2008 Jun; 15(12):885-901. PubMed ID: 18288208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.